BeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Increase from Citizens Jmp

BeOne Medicines (NASDAQ:ONC) had its price objective hoisted by equities research analysts at Citizens Jmp from $405.00 to $463.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp‘s target price suggests a potential upside of 13.77% from the stock’s previous close.

Other analysts have also issued research reports about the company. Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Wells Fargo & Company boosted their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday. JPMorgan Chase & Co. upped their price target on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, October 1st. Finally, Jefferies Financial Group restated a “buy” rating and issued a $470.00 price target on shares of BeOne Medicines in a report on Thursday. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $434.79.

BeOne Medicines Trading Up 5.1%

Shares of NASDAQ ONC opened at $406.96 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The business’s 50 day moving average price is $363.49 and its 200-day moving average price is $326.34. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $410.71. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 51.71 and a beta of 0.63.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a return on equity of 20.09% and a net margin of 13.86%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. On average, sell-side analysts expect that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Activity

In related news, CEO John Oyler sold 54,892 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the sale, the chief executive officer owned 240,743 shares in the company, valued at approximately $86,222,105.45. The trade was a 18.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Titus B. Ball sold 132 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $355.86, for a total value of $46,973.52. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 376,373 shares of company stock valued at $134,848,154. Insiders own 6.19% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of ONC. Mather Group LLC. lifted its holdings in shares of BeOne Medicines by 192.0% in the 3rd quarter. Mather Group LLC. now owns 73 shares of the company’s stock worth $27,000 after buying an additional 48 shares during the period. GAMMA Investing LLC increased its stake in shares of BeOne Medicines by 39.5% during the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock valued at $44,000 after buying an additional 34 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new position in shares of BeOne Medicines during the third quarter valued at $106,000. Provenance Wealth Advisors LLC purchased a new position in shares of BeOne Medicines during the third quarter valued at $106,000. Finally, Parallel Advisors LLC raised its holdings in shares of BeOne Medicines by 24.0% in the first quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after acquiring an additional 68 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.